The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO‐OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO)
Open accessAbstract
BACKGROUND: Primary surgery followed by platinum‐taxane based chemotherapy has been the standard therapy in advanced ovarian cancer. However, the prognostic role of complete and so‐called optimal and suboptimal debulking and its interaction with biological factors has not been not fully defined. METHODS: Exploratory analysis was conducted of 3 prospective randomized trials (AGO‐OVAR 3, 5, and 7) investigating platinum‐taxane based chemotherapy regimens in advanced ovarian cancer conducted between 1995 and 2002. RESULTS: A total of 3126 patients were analyzed. Approximately one‐third each fulfilled criteria for complete resection (group A), small residual tumor burden of 1‐10 mm (group B), or macroscopic residual disease exceeding 1 cm in diameter (group C). Multivariate analysis showed improved progression‐free and overall survival for group A with complete resection compared with groups B or C (P < .0001). The impact of so‐called optimal debulking as in group B showed a smaller prognostic impact compared with group C. Further independent prognostic factors for overall survival were age, performance status, grade, FIGO stage, and histology, namely the mucinous subtype. An interaction between residual tumor and some biologic factors was demonstrated. CONCLUSIONS: The goal of primary surgery should be complete resection. The prognostic impact of tumor biology seemed to be partially overruled by residual tumor and further evaluation of biologic factors should stratify for residual tumor. Cancer 2009. © 2009 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimating the Dimension of a Model
Schwarz, G. (1978) · The Annals of Statistics · doi:10.1214/aos/1176344136 · Cited by 47,033
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C., & Thun, M. J. (2006) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.56.2.106 · Cited by 5,314
Akaike, H. (1987) · Psychometrika · doi:10.1007/bf02294359 · Cited by 5,264
Estimates of the cancer incidence and mortality in Europe in 2006
Ferlay, J., Autier, P., Boniol, M., Heanue, M., Colombet, M., & Boyle, P. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl498 · Cited by 4,036
Akaike, H. (1987) · Springer Series in Statistics · doi:10.1007/978-1-4612-1694-0_29 · Cited by 4,027
Bristow, R. E., Tomacruz, R. S., Armstrong, D. K., Trimble, E. L., & Montz, F. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.5.1248 · Cited by 2,312
du Bois, A. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg036 · Cited by 1,113
Self-citationBenedet, J. L. (2000) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(00)00300-3 · Cited by 1,104
(2000) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(00)90001-8 · Cited by 891
Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study
Winter, W. E., Maxwell, G. L., Tian, C., Carlson, J. W., Ozols, R. F., Rose, P. G., Markman, M., Armstrong, D. K., Muggia, F., & McGuire, W. P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2517 · Cited by 845
Cited by
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Vergote, I., Tropé, C. G., Amant, F., Kristensen, G. B., Ehlen, T., Johnson, N., Verheijen, R. H. M., van der Burg, M. E. L., Lacave, A. J., Panici, P. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908806 · Cited by 2,537
Lheureux, S., Gourley, C., Vergote, I., & Oza, A. M. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32552-2 · Cited by 1,919
Jayson, G. C., Kohn, E. C., Kitchener, H. C., & Ledermann, J. A. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62146-7 · Cited by 1,850
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Epithelial ovarian cancer: Evolution of management in the era of precision medicine
Lheureux, S., Braunstein, M., & Oza, A. M. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21559 · Cited by 1,423
Kehoe, S., Hook, J., Nankivell, M., Jayson, G. C., Kitchener, H., Lopes, T., Luesley, D., Perren, T., Bannoo, S., Mascarenhas, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62223-6 · Cited by 1,414
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
Bowtell, D. D., Böhm, S., Ahmed, A. A., Aspuria, P.-J., Bast, R. C., Beral, V., Berek, J. S., Birrer, M. J., Blagden, S., Bookman, M. A., et al. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4019 · Cited by 1,367
Colombo, N., Sessa, C., du Bois, A., Ledermann, J., McCluggage, W. G., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz062 · Cited by 1,197
Self-citationLedermann, J. A., Raja, F. A., Fotopoulou, C., Gonzalez-Martin, A., Colombo, N., & Sessa, C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt333 · Cited by 1,104
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration
Altman, D. G., McShane, L. M., Sauerbrei, W., & Taube, S. E. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001216 · Cited by 1,013
Advances in ovarian cancer therapy
Cortez, A. J., Tudrej, P., Kujawa, K. A., & Lisowska, K. M. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3501-8 · Cited by 624
Coleman, R. L., Brady, M. F., Herzog, T. J., Sabbatini, P., Armstrong, D. K., Walker, J. L., Kim, B.-G., Fujiwara, K., Tewari, K. S., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30279-6 · Cited by 609
CA125 and Ovarian Cancer: A Comprehensive Review
Charkhchi, P., Cybulski, C., Gronwald, J., Wong, F. O., Narod, S. A., & Akbari, M. R. (2020) · Cancers · doi:10.3390/cancers12123730 · Cited by 602
Latest research and treatment of advanced-stage epithelial ovarian cancer
Coleman, R. L., Monk, B. J., Sood, A. K., & Herzog, T. J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.5 · Cited by 489
González-Martín, A., Harter, P., Leary, A., Lorusso, D., Miller, R. E., Pothuri, B., Ray-Coquard, I., Tan, D. S. P., Bellet, E., Oaknin, A., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.07.011 · Cited by 449
Self-citationChang, S.-J., Hodeib, M., Chang, J., & Bristow, R. E. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.05.040 · Cited by 433
Colombo, N., Sessa, C., Bois, A. D., Ledermann, J., McCluggage, W., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., et al. (2019) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2019-000308 · Cited by 407
Self-citationFagotti, A., Ferrandina, G., Vizzielli, G., Fanfani, F., Gallotta, V., Chiantera, V., Costantini, B., Margariti, P. A., Gueli Alletti, S., Cosentino, F., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.01.017 · Cited by 395
Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration
Altman, D. G., McShane, L. M., Sauerbrei, W., & Taube, S. E. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-51 · Cited by 372
Can advanced-stage ovarian cancer be cured?
Narod, S. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.224 · Cited by 369
Treatment of recurrent ovarian cancer
Pignata, S., C Cecere, S., Du Bois, A., Harter, P., & Heitz, F. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx441 · Cited by 338
Self-citationRandomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer
Harter, P., Sehouli, J., Vergote, I., Ferron, G., Reuss, A., Meier, W., Greggi, S., Mosgaard, B. J., Selle, F., Guyon, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103294 · Cited by 335
Self-citationHanker, L. C., Loibl, S., Burchardi, N., Pfisterer, J., Meier, W., Pujade-Lauraine, E., Ray-Coquard, I., Sehouli, J., Harter, P., & du Bois, A. (2012) · Annals of Oncology · doi:10.1093/annonc/mds203 · Cited by 329
Self-citationIncorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer
du Bois, A., Floquet, A., Kim, J.-W., Rau, J., del Campo, J. M., Friedlander, M., Pignata, S., Fujiwara, K., Vergote, I., Colombo, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.7348 · Cited by 328
Self-citationUpdates and New Options in Advanced Epithelial Ovarian Cancer Treatment
Kurnit, K. C., Fleming, G. F., & Lengyel, E. (2021) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000004173 · Cited by 322
Caruso, G., Weroha, S. J., & Cliby, W. (2025) · JAMA · doi:10.1001/jama.2025.9495 · Cited by 304
Böhm, S., Faruqi, A., Said, I., Lockley, M., Brockbank, E., Jeyarajah, A., Fitzpatrick, A., Ennis, D., Dowe, T., Santos, J. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.5212 · Cited by 303
Meng, X., Müller, V., Milde-Langosch, K., Trillsch, F., Pantel, K., & Schwarzenbach, H. (2016) · Oncotarget · doi:10.18632/oncotarget.7850 · Cited by 273
The Untapped Potential of Ascites in Ovarian Cancer Research and Treatment
Ford, C. E., Werner, B., Hacker, N. F., & Warton, K. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0875-x · Cited by 261
Karam, A., Ledermann, J. A., Kim, J.-W., Sehouli, J., Lu, K., Gourley, C., Katsumata, N., Burger, R. A., Nam, B.-H., Bacon, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx011 · Cited by 153
Self-citationDeterminants of quality of life in ovarian cancer survivors: a pilot study
Teng, F. F., Kalloger, S. E., Brotto, L., & McAlpine, J. N. (2014) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(15)30513-2 · Cited by 42
Port site resection after laparoscopy in advance ovarian cancer surgery: time to abandon?
Lago, V., Gimenez, L., Matute, L., Padilla-Iserte, P., Cárdenas-Rebollo, J. M., Gurrea, M., Montero, B., Montoliu, G., & Domingo, S. (2019) · Surgical Oncology · doi:10.1016/j.suronc.2019.01.007 · Cited by 18
Metadata
- Authors
- du Bois, A., Reuss, A., Pujade‐Lauraine, E., Harter, P., Ray‐Coquard, I., & Pfisterer, J.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2009-02-02
- Volume
- 115
- Issue
- 6
- Pages
- 1234-1244
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1964736695
- Cited by
- 1,638
- References
- 29
- FWCI
- 52.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.